Literature DB >> 14709759

Update on psychotropic medication use in renal disease.

Lewis M Cohen1, Edward G Tessier, Michael J Germain, Norman B Levy.   

Abstract

Renal failure is a common medical condition, and many patients have comorbid psychiatric disorders. In this review, which is intended as a resource for consultation psychiatrists, the authors discuss pharmacokinetic considerations and provide information about the use of individual psychotropic medications in patients with renal disease. Most psychotropic medications are fat soluble, easily pass the blood-brain barrier, are not dialyzable, are metabolized primarily by the liver, and are excreted mainly in bile. Consequently, the majority of these drugs can be safely used with the end-stage renal disease population.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14709759     DOI: 10.1176/appi.psy.45.1.34

Source DB:  PubMed          Journal:  Psychosomatics        ISSN: 0033-3182            Impact factor:   2.386


  12 in total

1.  Patterns and predictors of depression treatment among adults with chronic kidney disease and depression in ambulatory care settings in the United States.

Authors:  Nina Vadiei; Sandipan Bhattacharjee
Journal:  Int Urol Nephrol       Date:  2018-12-04       Impact factor: 2.370

2.  "Should I go on dialysis, Doc?": initiating dialysis in elderly patients with end-stage renal disease.

Authors:  Dori Seccareccia; James Downar
Journal:  Can Fam Physician       Date:  2012-12       Impact factor: 3.275

Review 3.  Consequences of CKD on Functioning.

Authors:  Piyawan Kittiskulnam; Anoop Sheshadri; Kirsten L Johansen
Journal:  Semin Nephrol       Date:  2016-07       Impact factor: 5.299

4.  Therapeutic drug monitoring of antidepressants in haemodialysis patients.

Authors:  Stefan Unterecker; Philip Müller; Christian Jacob; Peter Riederer; Bruno Pfuhlmann
Journal:  Clin Drug Investig       Date:  2012-08-01       Impact factor: 2.859

Review 5.  Epidemiology, diagnosis, and management of depression in patients with CKD.

Authors:  S Susan Hedayati; Fredric O Finkelstein
Journal:  Am J Kidney Dis       Date:  2009-07-09       Impact factor: 8.860

6.  Course of depression and anxiety diagnosis in patients treated with hemodialysis: a 16-month follow-up.

Authors:  Daniel Cukor; Jeremy Coplan; Clinton Brown; Rolf A Peterson; Paul L Kimmel
Journal:  Clin J Am Soc Nephrol       Date:  2008-08-06       Impact factor: 8.237

7.  Rationale and design of the Chronic Kidney Disease Antidepressant Sertraline Trial (CAST).

Authors:  Nishank Jain; Madhukar H Trivedi; A John Rush; Thomas Carmody; Benji Kurian; Robert D Toto; Ravindra Sarode; S Susan Hedayati
Journal:  Contemp Clin Trials       Date:  2012-10-22       Impact factor: 2.226

Review 8.  Depression in Chronic Kidney Disease and End-Stage Renal Disease: Similarities and Differences in Diagnosis, Epidemiology, and Management.

Authors:  Shayan Shirazian; Candace D Grant; Olufemi Aina; Joseph Mattana; Farah Khorassani; Ana C Ricardo
Journal:  Kidney Int Rep       Date:  2016-09-20

9.  Higher anti-depressant dose and major adverse outcomes in moderate chronic kidney disease: a retrospective population-based study.

Authors:  Varun Dev; Stephanie N Dixon; Jamie L Fleet; Sonja Gandhi; Tara Gomes; Ziv Harel; Arsh K Jain; Salimah Z Shariff; Davy Tawadrous; Matthew A Weir; Amit X Garg
Journal:  BMC Nephrol       Date:  2014-05-10       Impact factor: 2.388

Review 10.  Pharmacological and Non-pharmacological Treatment Options for Depression and Depressive Symptoms in Hemodialysis Patients.

Authors:  Stefania S Grigoriou; Christina Karatzaferi; Giorgos K Sakkas
Journal:  Health Psychol Res       Date:  2015-04-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.